FDA Clears Non-Invasive Device to Treat Chronic Intractable Pain

The device uses a hybrid pulsed radio frequency waveform to provide relief of chronic intractable pain
The device uses a hybrid pulsed radio frequency waveform to provide relief of chronic intractable pain

Xavant Technology announced that their non-invasive neuromodulation device Stimpod NMS460 has been cleared by the Food and Drug Administration (FDA).

The Stimpod NMS460 device uses a patented hybrid pulsed radio frequency (PRF) waveform transcutaneously to provide symptomatic relief and management of chronic intractable pain. The device is also indicated as an adjunctive treatment for the management of post-surgical pain, post-traumatic acute pain, and for pain control due to rehabilitation. 

The Stimpod NMS460 includes a nerve-mapping pen-like probe which allows practitioners to locate nerves and evaluate the treatment progress. 

Related Articles

“This technology […] is a valuable treatment asset for neurologists, chiropractors, acupuncturists, physical therapists, physiatrists, and medical pain practitioners,” said Corlius Birkill, CEO of Xavant Technology.

Xavant Technology produces a line of nerve stimulators for regional and general anesthesia applications. As well as NMS460, the Stimpod range includes the NMS410 for precise nerve location and the NMS450 for nerve location and neuromuscular blocking agent monitoring.

Bell Medical has been selected as the distributor for the U.S. market.

For more information visit Stimpodnms460.com.